Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Nebulized arformoterol: what is its place in the management of COPD?

Miles MC, Donohue JF, Ohar JA.

Ther Adv Respir Dis. 2013 Apr;7(2):81-6. doi: 10.1177/1753465812465784. Epub 2012 Nov 12. Review.

PMID:
23147985
2.

Review of drug safety and efficacy of arformoterol in chronic obstructive pulmonary disease.

Loh CH, Donohue JF, Ohar JA.

Expert Opin Drug Saf. 2015 Mar;14(3):463-72. doi: 10.1517/14740338.2015.998196. Epub 2015 Jan 7. Review.

PMID:
25563342
3.

Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.

Baumgartner RA, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Hanrahan JP.

Clin Ther. 2007 Feb;29(2):261-78.

PMID:
17472819
4.

A pharmacokinetic/pharmacodynamic study comparing arformoterol tartrate inhalation solution and racemic formoterol dry powder inhaler in subjects with chronic obstructive pulmonary disease.

Kharidia J, Fogarty CM, Laforce CF, Maier G, Hsu R, Dunnington KM, Curry L, Baumgartner RA, Hanrahan JP.

Pulm Pharmacol Ther. 2008 Aug;21(4):657-62. doi: 10.1016/j.pupt.2008.03.003. Epub 2008 Apr 7.

PMID:
18501650
5.

Hospital readmissions following initiation of nebulized arformoterol tartrate or nebulized short-acting beta-agonists among inpatients treated for COPD.

Bollu V, Ernst FR, Karafilidis J, Rajagopalan K, Robinson SB, Braman SS.

Int J Chron Obstruct Pulmon Dis. 2013;8:631-9. doi: 10.2147/COPD.S52557. Epub 2013 Dec 5.

6.

Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate.

Mahler DA, Waterman LA, Ward J, Gifford AH.

J Aerosol Med Pulm Drug Deliv. 2014 Apr;27(2):103-9. doi: 10.1089/jamp.2013.1038. Epub 2013 Jun 8.

PMID:
23745526
7.

Budesonide/formoterol combination in COPD: a US perspective.

Sharafkhaneh A, Mattewal AS, Abraham VM, Dronavalli G, Hanania NA.

Int J Chron Obstruct Pulmon Dis. 2010 Oct 5;5:357-66. doi: 10.2147/COPD.S4215. Review.

8.

The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD.

Papi A, Jones PW, Dalvi PS, McAulay K, McIver T, Dissanayake S.

Int J Chron Obstruct Pulmon Dis. 2015 Nov 9;10:2431-8. doi: 10.2147/COPD.S93375. eCollection 2015.

9.

Arformoterol tartrate in the treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease.

Madaan A.

Drugs Today (Barc). 2009 Jan;45(1):3-9. doi: 10.1358/dot.2009.45.1.1313983.

PMID:
19271027
10.

Arformoterol tartrate in the treatment of COPD.

Cazzola M, Hanania NA, Matera MG.

Expert Rev Respir Med. 2010 Apr;4(2):155-62. doi: 10.1586/ers.10.16. Review.

PMID:
20406080
11.

Role of arformoterol in the management of COPD.

King P.

Int J Chron Obstruct Pulmon Dis. 2008;3(3):385-91. Review.

12.

Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD.

Tashkin DP, Donohue JF, Mahler DA, Huang H, Goodwin E, Schaefer K, Hanrahan JP, Andrews WT.

Respir Med. 2009 Apr;103(4):516-24. doi: 10.1016/j.rmed.2008.12.014. Epub 2009 Feb 8.

13.

Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.

Spencer S, Karner C, Cates CJ, Evans DJ.

Cochrane Database Syst Rev. 2011 Dec 7;(12):CD007033. doi: 10.1002/14651858.CD007033.pub3. Review.

PMID:
22161409
14.

Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.

Spencer S, Evans DJ, Karner C, Cates CJ.

Cochrane Database Syst Rev. 2011 Oct 5;(10):CD007033. doi: 10.1002/14651858.CD007033.pub2. Review. Update in: Cochrane Database Syst Rev. 2011;(12):CD007033.

PMID:
21975759
15.

One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD.

Donohue JF, Hanania NA, Make B, Miles MC, Mahler DA, Curry L, Tosiello R, Wheeler A, Tashkin DP.

Chest. 2014 Dec;146(6):1531-42. doi: 10.1378/chest.14-0117.

16.

Indacaterol 75 μg once daily for the treatment of patients with chronic obstructive pulmonary disease: a North American perspective.

Kerwin EM, Williams J.

Ther Adv Respir Dis. 2013 Feb;7(1):25-37. doi: 10.1177/1753465812470018. Epub 2013 Jan 7. Review.

PMID:
23296242
17.

Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.

Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C.

Clin Ther. 2012 Aug;34(8):1655-66.e5. doi: 10.1016/j.clinthera.2012.06.005. Epub 2012 Jul 11.

PMID:
22789766
18.

Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials.

Hanrahan JP, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Baumgartner RA.

COPD. 2008 Feb;5(1):25-34. doi: 10.1080/15412550701816187.

PMID:
18259972
19.

Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients.

Gross NJ, Nelson HS, Lapidus RJ, Dunn L, Lynn L, Rinehart M, Denis-Mize K; Formoterol Study Group..

Respir Med. 2008 Feb;102(2):189-97.

PMID:
18363201
20.

Comparison of the efficacy and safety of arformoterol 15 microg twice daily and arformoterol 30 microg once daily in COPD: a single-dose, multicenter, randomized, modified-blind, two-way crossover study.

Panettieri RA Jr, MacIntyre N, Sims M, Kerwin E, Fogarty C, Noonan M, Claus R, Andrews WT.

Clin Ther. 2009 Aug;31(8):1716-23. doi: 10.1016/j.clinthera.2009.08.012.

PMID:
19808130

Supplemental Content

Support Center